The documents for the clinical tests were submitted to the Ethics Committee of the University Hospital in Tübingen towards the end of March. The approval for the test, the measurement catheter developed in cooperation with Nanoscale GmbH, should be available by the end of April. After that, the application will be tested for approximately 4 weeks. A period of approximately 8 months is expected for use in humans. The clinical tests will be carried out in parallel at 5 different clinics and will last a total of approximately 18 months. This is the first step for the approval of nano3DSense™ in Europe via Germany.
